Antibodies to LGE.sub.2 -protein antigens

Details Antibodies to LGE.sub.2 -protein antigens Antibodies to LGE.sub.2 -protein antigens

1996-07-31

1997-11-11

Feisee, Lila

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 792, 5303871, 436 13, 436 71, 436 88, G01N 3353, G01N 3392, C07K 1600

Patent

active

056862504

ABSTRACT:
Levuglandin (LG) derivatives are used as antigens for raising antibodies useful in diagnostic assays. The antibodies produced by LG-carrier protein adducts can be used to detect adducts of LGE.sub.2 with human low density lipoprotein (LDL). LGE.sub.2 -protein adduct immunoreactivity may be generated during in vitro free-radical oxidation of LDL. An enzyme-linked immunosorbent assay for detecting adducts of LGE.sub.2 with human LDL is also described.

REFERENCES:
Goldyne, Prostaglandins & Other Eicosanoids, Appelton & Lange, Los Altos, CA, 1987, 211-221.
Zubay, Biochemistry, 1983, Addison-Wesley, Reading, Mass p. 555.
Leninger et al, Principles of Biochemistry, 1993, Worth Pub, NY, pp. 258 & 656.
J.T. Shepherd, et al., "Report of the Task Force on Vascular Medicine," Circulation 89(1):532-35 (1994).
D. Driscoll et al. "Guidelines for Evaluation and Management of Common Congenital Cardiac Problems in Infants, Children, and Adolescents," Circulation 90(4):2180-88 (1994).
M.S. Remetz and R.A. Matthay, "Cardiac Evaluation," Disease-a-Month 38(6):338-503 (1992).
K.M. Coy et al., "Intravascular Ultrasound Imaging: A Current Perspective," J. Am. Coll. Cardiol. 18(7):1811-23 (1991).
S. Sirna et al., "Cardiac Evaluation of the Patient With Stroke," Stroke 21(1):14-23 (1990).
C.B. Higgins and G.R. Caputo, "Role of MR Imaging in Acquired and Congenital Cardiovascular Disease," AJR 161:13-22 (1993).
M. Tervahauta et al., "Prevalence Of Coronary Heart Disease and Associated Risk Factors Among Elderly Finnish Men in the Seven Countries Study," Atherosclerosis 104:47-59 (1993).
J.L. Breslow, "Genetics of Lipoprotein Disorders," Circulation 87:(supp. III):III-16--III-21 (1993).
E.J. Schaefer et al. "Familial lipoprotein disorders and premature coronary artery disease," Atherosclerosis 108(Supp):S41-S54 (1994).
B.A. Nassar, "Familial defective apolipoprotein B-100: a cause of hypercholesterolemia and early coronary heart disease," Can. Med. Assoc. J. 148(4):579-80 (1993).
A. Tybjaerg-Hansen et al., "Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten cases," Atheroscelerosis 80:235-42 (1990).
J. Woo et al., "Lipids, lipoproteins and other coronary risk factors in Chinese male survivors of myocardial infarction," Intl. J. Card. 39:195-202 (1993).
W.B. Kannel and P.W.F. Wilson, "Efficacy of lipid profiles in prediction of coronary disease," Am. Heart J. 124(3):768-74 (1992).
M.E. Goldyne, "Prostaglandins & Other Eicosanoids," in Basic And Clinical Pharmacology, Ch. 17, pp. 211-221; B.G. Katzung, ed., (Appleton & Lange, Los Altos, CA) (3rd Ed., 1987).
D. Steinberg et al., "Beyond Choleterol: Modifications of Low-Density Lipoprotein That Increase Its Atherogenicity," N. Eng. J. Med. 320:915-24 (1989).
S. Parthasarathy et al., "The Role of Oxidized Low-Density Lipoproteins in Pathogenesis of Atherosclerosis," Annu. Rev. Med. 43:219-25 (1992).
H. Easterbauer et al., "Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes," J. Lipid Res. 28:495 (1987).
A.M. Fogelman et al., "Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages," Proc. Natl. Acad. Sci. USA 77:2214-18 (1980).
G.J. Jurgens et al., "Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal," Biochim. Biophys. Acta 875:103-14 (1986).
F. Hayase et al., "Aging of Proteins: Immunological Detection Of A Glucose-Derived Pyrrole Formed During Maillard Reaction In Vivo," J. Biol. Chem. 263:3758-64 (1989).
S. Miyata and V. Monnier, "Immunohistochemical Detection Of Advanced Glycosylation End Products In Diabetic Tissues Using Monoclonal Antibody To Pyrraline," J. Clin. Invest. 89:1102-12 (1992).
S. Kim, "Part 1. Halichondrin B: Synthesis Of An H-Ring Intermediate; Part 2. Levuglandin-Protein Adducts: Synthesis Of An Antigen For Immunoassay", Thesis, Case Western Reserve University (1992).
K.K. Murthi, "Chapter 2. Levuglandins: Detection And Biological Chemistry," Thesis, Case Western Reserve University (1992).
E. DiFranco, "Part II. An Immunoassay For Protein-Bound Levuglandin-Derived Pyrroles," Thesis, Case Western Reserve University (1994).
R.A. Fishman and P.H, Chan, "Hypothesis: Membrane Phospholipid Degradation and Polyunsaturated Fatty Acids Play a Key Role in the Pathogenesis of Brain Edema", Trans. Am. Neuro. Assoc. 106:1 (1981).
M. Hamberg and B. Samuelsson, "Detection and Isolation of an Endoperoxide Intermediate in Protaglandin Biosynthesis," Proc. Natl. Acad. Sci. USA 70:899-903 (1973).
M. Hamberg et al., "Isolation and Structure of Two Prostaglandin Endoperoxides That Cause Platelet Aggregation," Proc. Natl. Acad. Sci. USA 71:345-49 (1974).
A. Raz et al., "Effect of Organic Sulfur Compounds on the Chemical Enzymatic Transformation of Prostaglandin Endoperoxide H.sub.2," Biochim. Biophys. Acta 488:322-29 (1977).
D.H. Nugteren and E. Christ-Hazelhof, "Chemical and Enzymic Conversions of the Prostaglandin Endoperoxide PGH.sub.2," Adv. Prostaglandin Thromboxane Res. 6:129-37 (1980).
R.G. Salomon et al., "Solvent-Induced Fragmentation of Prostaglandin Endoperoxides. New Aldehyde Products from PGH.sub.2 and a Novel Intramolecular 1,2-Hydride Shift during Endoperoxide Fragmentation in Aqueous Solution," J. Am. Chem. Soc. 106:6049-60 (1984).
R.G. Salomon et al., "Prostaglandins Endoperoxides 21. Covalent Binding Of Levuglandin E.sub.2 With Proteins," Prostaglandins 34:643-56 (1987).
R. Iyer et al., "Generation Of Pyrroles In The Reaction Of Levuglandin E.sub.2 With Proteins," J. Org. Chem. 59:6038-6043 (1994).
S.M. Lynch et al., "Formation of Non-cyclooxygenase-derived Prostanoids (F.sub.2 -Isoprostanes) in Plasma and Low Density Lipoprotein Exposed to Oxidative Stress in Vitro," J. Clin. Invest. 93:998-1004 (1994).
J.D. Morrow et al., "Noncyclooxygenase Oxidative Formation of a Series of Novel Prostaglandins: Analytical Ramifications for Measurement of Eicosanoids," Anal. Biochem. 184:1-10 (1990).
U.P. Steinbrecher et al., "Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids," Proc. Natl. Acad. Sci. USA 81:3883-87 (1984).
U.P. Steinbrecher et al., "Decrease in Reactive Amino Groups during Oxidation or Endothelial Cell Modification of LDL," Atherosclerosis 7:135-43 (1987).
U.P. Steinbrecher, "Oxidation of Human Low Density Lipoprotein Results in Derivatization of Lysine Residues of Apolipoprotein B by Lipid Peroxide Decomposition Products," J. Biol. Chem. 262:3603-08 (1987).
U.P. Steinbrecher and P.H. Pritchard, "Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase," J. Lipid Res. 30:305-15 (1989).
S. Parthasarathy and J. Barnett, "Phospholipase A.sub.2 activity of low density lipoprotein: Evidence for an intrinsic phospholipase A.sub.2 activity of apoprotein B-100," Proc. Natl. Acad. Sci. USA 87:9741-45 (1990).
N. Reisfeld et al., "Aplipoprotein B exhibits phospholipase A.sub.1 and phospholipase A.sub.2 activities," FEBS Lett. 315:267-70 (1993).
J.D. Morrow et al., "A series of prostaglandin F.sub.2 -like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism," Proc. Natl. Acad. Sci. USA 87:9383-87 (1990).
M.F. White, et al., "The Insulin Signaling System," J. Biol. Chem. 269:1-4 (1994).
R.G. Salomon, Accounts Chem. Res. 18:294 (1985).
E. DiFranco et al., Chem. Res. Toxicol. 8:61-67 (1995).
A. Voller and D. Bidwell, in Manual of Clinical Laboratory Immunology (N.R. Rose et al., eds.; American Society For Microbiology, Washington D.C.) pp. 99-109 (3rd Ed. 1986).
D.B. Miller et al., "Levuglandin E.sub.2 : Enantiocontrolled Total Synthesis of a Biologically Active Rearrangement Product from the Prostaglandin Endoperoxide PGH.sub.2," J. Org. Chem. 55:3164-75 (1990).
Baker, "Carbohydrate Thioacetals. I. Lead Tetraacetate Oxidation of D-Arabinose Derivatives," J. Am. Chem. Soc. 74:827 (1952).
M.E. Kobie

Affiliated with

Also associated with

Rating

Antibodies to LGE.sub.2 -protein antigens does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to LGE.sub.2 -protein antigens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to LGE.sub.2 -protein antigens will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1227841